A Phase II Study of Gemcitabine and Bexarotene (GemBex) in the Treatment of Cutaneous T-Cell Lymphoma

doi 10.1186/isrctn18563749
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Ten-Year Experience of Bexarotene Therapy for Cutaneous T-Cell Lymphoma in Finland

Acta Dermato-Venereologica
DermatologyMedicine
2012English

Long‐term Efficacy and Safety of Bexarotene for Japanese Patients With Cutaneous T‐cell Lymphoma: The Results of a Phase 2 Study (B‐1201)

Journal of Dermatology
DermatologyMedicine
2019English

Laboratory Correlates for a Phase II Trial of Romidepsin in Cutaneous and Peripheral T-Cell Lymphoma

British Journal of Haematology
Hematology
2010English

Treatment of Cutaneous T-Cell Lymphoma: An Update

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1993English

Orphan Designation: Mogamulizumab, Treatment of Cutaneous T-Cell Lymphoma

Case Medical Research
2019English

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2018English

676 Exploring Novel Therapeutic Targets in the Treatment of Cutaneous T-Cell Lymphoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Infectious Complications of Cutaneous T-Cell Lymphoma

Cancer Control
MedicineOncologyHematology
2001English

Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Bőrgyógyászati és Venerológiai Szemle
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy